Connect Biopharma Holdings Limited's Customers Performance

Name: Connect Biopharma Holdings Limited Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CNTB

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CNTB's Source of Revenues		During the corresponding time, Connect Biopharma Holdings Limited recorded a revenue increase by 5666.67 % year on year, sequentially revenue grew by 1537.87 %. While revenue at the Connect Biopharma Holdings Limited's corporate clients • List of CNTB Customers

for the same period Connect Biopharma Holdings Limited recorded revenue increase by 5666.67 % year on year, sequentially revenue grew by 1537.87 %.

• List of CNTB Customers

Connect Biopharma Holdings Limited's Business Units


Treatment of Respiratory Diseases		106.11 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Connect Biopharma Holdings Limited's Comment on Sales, Marketing and Customers

The text outlines regulatory and legal frameworks impacting the business, including privacy and data protection laws, environmental, health and safety regulations, and various laws and regulations of the People's Republic of China related to company establishment and foreign investment.

News about Connect Biopharma Holdings Limited Contracts

Connect Biopharma's Rademikibart Shows Promise as a Breakthrough Treatment for Atopic Dermatitis in China Trial

Connect Biopharma Announces Positive Long-Term Data from China Trial, Boosting Prospects for Rademikibart in Atopic Dermatitis Treatment
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company, has released positive topline results from the Stage 2 of its China pivotal trial evaluating the efficacy and safety of rademikibarts (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis (AD). This announcement follows the successful Stage 1 results of the trial, in which all primary and key secondary endpoints were met.
Atopic dermatitis is a chronic inflammatory skin condition characterized by itchy, red, and swollen skin. It affects millions of peo...

Connect Biopharma Holdings Limited’s Comment on Sales, Marketing and Customers

CNTB's Stock Performance relative to it's Customers

CNTB's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Connect Biopharma Holdings Limited	77.98	0.00	-64.61	64
SUBTOTAL	0.00	0.00	0.00	-

Sources: Connect Biopharma Holdings Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Connect Biopharma Holdings Limited’s corporate clients.
For your research, we’ve provided 9 tables on Connect Biopharma Holdings Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.